<DOC>
	<DOCNO>NCT02002325</DOCNO>
	<brief_summary>The purpose study clarify efficacy safety MRI-based intravenous thrombolysis alteplase patient acute wake-up ischemic stroke acute ischemic stroke unknown time symptom onset .</brief_summary>
	<brief_title>THrombolysis Acute Wake-up Unclear-onset Strokes With Alteplase 0.6 mg/kg Trial ( THAWS )</brief_title>
	<detailed_description>THAWS investigator initiate Japanese multicenter randomize controlled clinical trial MRI base thrombolysis patient acute wake-up ischemic stroke acute ischemic stroke unknown time symptom onset . Intravenous thrombolysis alteplase 0.6mg/kg , different 0.9mg/kg used country , available effective safe treatment acute stroke within 4.5 hour symptom onset Japan . However , time symptom onset unknown 25 % acute stroke patient . These patient currently exclude intravenous thrombolysis alteplase . The objective THAWS project provide effective treatment option acute stroke patient unknown time symptom onset . The purpose study clarify efficacy safety MRI-based intravenous thrombolysis alteplase 0.6mg/kg patient acute wake-up ischemic stroke acute ischemic stroke unknown time symptom onset . Eligible patient select base MRI finding indicative acute ischemic stroke le 4.5 hour age .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Clinical diagnosis acute ischemic stroke unknown symptom onset ( e.g . acute wakeup ischemic stroke , acute ischemic stroke unknown time symptom onset ) Last know well without neurological symptom &gt; 4.5 hour treatment initiation Treatment start within 4.5 hour symptom recognition ( e.g . awake ) Acute stroke MRI include diffusion weight imaging ( DWI ) fluid attenuate inversion recovery ( FLAIR ) complete Alberta Stroke Program Early CT score ( ASPECTS ) initial DWI 5 No mark parenchymal hyperintensity visible FLAIR Initial NIHSS ≥2 Written inform consent patient next kin Prestroke Modified Rankin Scale ( mRS ) &gt; 1 ( patient inability carry daily activity require help supervision ) Contraindications Japanese guideline intravenous application recombinant tissuetype plasminogen activator ( alteplase ) History nontraumatic intracranial hemorrhage History stroke within last 1 month ( exclude transient ischemic attack ) History significant head/spinal injury surgery within last 3 month History gastrointestinal urinary tract bleed within last 21 day History major surgery significant trauma head injury within last 14 day Hypersensitivity alteplase Suspected subarachnoid hemorrhage Concurrent acute aortic dissection Concurrent hemorrhage ( e.g. , intracranial , gastrointestinal , urinary tract , retroperitoneal , hemoptysis ) Systolic blood pressure ≥185 mmHg despite antihypertensive therapy Diastolic blood pressure ≥110 mmhg despite antihypertensive therapy Significant hepatic disorder Acute pancreatitis Blood glucose &lt; 50mg/dL &gt; 400 mg/dL Platelet count ≤100,000/mm3 International normalize ratio prothrombin time ( PTINR ) &gt; 1.7 Prolonged activate partial thromboplastin time ( aPTT : &gt; 1.5 time baseline value [ &gt; approximately 40 second guide ] ) patient anticoagulation therapy abnormal coagulation Any contraindication MRI ( e.g . cardiac pacemaker ) Extensive early ischemic change brain stem cerebellum ( e.g. , half brain stem one hemisphere cerebellum ) Planned anticipate treatment surgery endovascular reperfusion strategy ( e.g. , intraarterial thrombolysis , mechanical recanalization technique ) Pregnant , lactating , potentially pregnant Life expectancy 6 month less judgment investigator Inappropriate study enrollment judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>